Last reviewed · How we verify
Vumide — Competitive Intelligence Brief
phase 2
Sodium-dependent neutral amino acid transporter B(0)AT1
Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Vumide (CINROMIDE). Vumide works by binding to the sodium-dependent neutral amino acid transporter B(0)AT1, which is involved in the transport of certain amino acids across cell membranes.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Vumide TARGET | CINROMIDE | phase 2 | Sodium-dependent neutral amino acid transporter B(0)AT1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Vumide — Competitive Intelligence Brief. https://druglandscape.com/ci/cinromide. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing